Can a transplant drug stop COVID lung damage?
NCT ID NCT04948203
First seen Jan 06, 2026 · Last updated May 12, 2026 · Updated 17 times
Summary
This study tests whether the drug sirolimus can prevent long-term lung scarring (pulmonary fibrosis) in people hospitalized with severe COVID-19 pneumonia. About 60 adults who need extra oxygen will receive sirolimus to see if it reduces the chance of developing fibrosis. The goal is to stop lasting lung damage and improve recovery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LONG COVID are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Chicago
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.